Growth hormone treatment and aortic dimensions in turner syndrome

Carolyn A. Bondy, Phillip Van, Vladimir K. Bakalov, Vincent B. Ho

Research output: Contribution to journalArticle

Abstract

Background: In recent years many girls with Turner syndrome (TS) have been treated with supraphysiological doses of GH to increase adult height. In addition to promoting statural growth, GH may have direct effects on the cardiovascular system. Objective: We sought to determine whether GH treatment affects aortic diameter in girls with TS because there is an increased risk for aortic dilation and dissection in this syndrome. Methods: In a retrospective, cross-sectional study, we compared ascending and descending aortic diameters measured by magnetic resonance imaging in GH-treated (n=53) vs. untreated (n=8) patients with TS participating in a National Institutes of Health protocol between 2001 and 2004. Results: The average duration of GH treatment was 4.7 with SE 0.4 yr (range 2-11 yr). The two groups were similar in age and weight, but GH-treated subjects were on average 8 cm taller (P = 0.002). The diameter of the ascending aorta was increased by 7.3% and descending aorta by 8.9% in the GH-treated group. However, after correction for age, height, weight, and presence of bicuspid aortic valve and coarctation, using a multiple regression, neither history of GH treatment nor the length of GH treatment had an effect on the aortic diameter. Weight (P = 0.02), height (P = 0.001), and presence of bicuspid aortic valve (P = 0.0001) were associated with larger ascending aortic diameter, whereas age (P = 0.008), height (P = 0.02), and history of coarctation (P = 0.006) were associated with larger descending aortic diameter. Conclusions: GH treatment of girls with TS does not seem to affect ascending or descending aortic diameter above the increase related to the larger body size.

Original languageEnglish (US)
Pages (from-to)1785-1788
Number of pages4
JournalJournal of Clinical Endocrinology and Metabolism
Volume91
Issue number5
DOIs
StatePublished - May 1 2006
Externally publishedYes

Fingerprint

Cardiovascular system
Dissection
Turner Syndrome
Magnetic resonance
Growth Hormone
Health
Imaging techniques
Weights and Measures
Therapeutics
Aortic Coarctation
National Institutes of Health (U.S.)
Body Size
Cardiovascular System
Thoracic Aorta
Aorta
Dilatation
Cross-Sectional Studies
Magnetic Resonance Imaging
Growth

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Growth hormone treatment and aortic dimensions in turner syndrome. / Bondy, Carolyn A.; Van, Phillip; Bakalov, Vladimir K.; Ho, Vincent B.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 91, No. 5, 01.05.2006, p. 1785-1788.

Research output: Contribution to journalArticle

Bondy, Carolyn A. ; Van, Phillip ; Bakalov, Vladimir K. ; Ho, Vincent B. / Growth hormone treatment and aortic dimensions in turner syndrome. In: Journal of Clinical Endocrinology and Metabolism. 2006 ; Vol. 91, No. 5. pp. 1785-1788.
@article{2563b0f71ca6432da6fbf289867132fc,
title = "Growth hormone treatment and aortic dimensions in turner syndrome",
abstract = "Background: In recent years many girls with Turner syndrome (TS) have been treated with supraphysiological doses of GH to increase adult height. In addition to promoting statural growth, GH may have direct effects on the cardiovascular system. Objective: We sought to determine whether GH treatment affects aortic diameter in girls with TS because there is an increased risk for aortic dilation and dissection in this syndrome. Methods: In a retrospective, cross-sectional study, we compared ascending and descending aortic diameters measured by magnetic resonance imaging in GH-treated (n=53) vs. untreated (n=8) patients with TS participating in a National Institutes of Health protocol between 2001 and 2004. Results: The average duration of GH treatment was 4.7 with SE 0.4 yr (range 2-11 yr). The two groups were similar in age and weight, but GH-treated subjects were on average 8 cm taller (P = 0.002). The diameter of the ascending aorta was increased by 7.3{\%} and descending aorta by 8.9{\%} in the GH-treated group. However, after correction for age, height, weight, and presence of bicuspid aortic valve and coarctation, using a multiple regression, neither history of GH treatment nor the length of GH treatment had an effect on the aortic diameter. Weight (P = 0.02), height (P = 0.001), and presence of bicuspid aortic valve (P = 0.0001) were associated with larger ascending aortic diameter, whereas age (P = 0.008), height (P = 0.02), and history of coarctation (P = 0.006) were associated with larger descending aortic diameter. Conclusions: GH treatment of girls with TS does not seem to affect ascending or descending aortic diameter above the increase related to the larger body size.",
author = "Bondy, {Carolyn A.} and Phillip Van and Bakalov, {Vladimir K.} and Ho, {Vincent B.}",
year = "2006",
month = "5",
day = "1",
doi = "10.1210/jc.2005-2625",
language = "English (US)",
volume = "91",
pages = "1785--1788",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "5",

}

TY - JOUR

T1 - Growth hormone treatment and aortic dimensions in turner syndrome

AU - Bondy, Carolyn A.

AU - Van, Phillip

AU - Bakalov, Vladimir K.

AU - Ho, Vincent B.

PY - 2006/5/1

Y1 - 2006/5/1

N2 - Background: In recent years many girls with Turner syndrome (TS) have been treated with supraphysiological doses of GH to increase adult height. In addition to promoting statural growth, GH may have direct effects on the cardiovascular system. Objective: We sought to determine whether GH treatment affects aortic diameter in girls with TS because there is an increased risk for aortic dilation and dissection in this syndrome. Methods: In a retrospective, cross-sectional study, we compared ascending and descending aortic diameters measured by magnetic resonance imaging in GH-treated (n=53) vs. untreated (n=8) patients with TS participating in a National Institutes of Health protocol between 2001 and 2004. Results: The average duration of GH treatment was 4.7 with SE 0.4 yr (range 2-11 yr). The two groups were similar in age and weight, but GH-treated subjects were on average 8 cm taller (P = 0.002). The diameter of the ascending aorta was increased by 7.3% and descending aorta by 8.9% in the GH-treated group. However, after correction for age, height, weight, and presence of bicuspid aortic valve and coarctation, using a multiple regression, neither history of GH treatment nor the length of GH treatment had an effect on the aortic diameter. Weight (P = 0.02), height (P = 0.001), and presence of bicuspid aortic valve (P = 0.0001) were associated with larger ascending aortic diameter, whereas age (P = 0.008), height (P = 0.02), and history of coarctation (P = 0.006) were associated with larger descending aortic diameter. Conclusions: GH treatment of girls with TS does not seem to affect ascending or descending aortic diameter above the increase related to the larger body size.

AB - Background: In recent years many girls with Turner syndrome (TS) have been treated with supraphysiological doses of GH to increase adult height. In addition to promoting statural growth, GH may have direct effects on the cardiovascular system. Objective: We sought to determine whether GH treatment affects aortic diameter in girls with TS because there is an increased risk for aortic dilation and dissection in this syndrome. Methods: In a retrospective, cross-sectional study, we compared ascending and descending aortic diameters measured by magnetic resonance imaging in GH-treated (n=53) vs. untreated (n=8) patients with TS participating in a National Institutes of Health protocol between 2001 and 2004. Results: The average duration of GH treatment was 4.7 with SE 0.4 yr (range 2-11 yr). The two groups were similar in age and weight, but GH-treated subjects were on average 8 cm taller (P = 0.002). The diameter of the ascending aorta was increased by 7.3% and descending aorta by 8.9% in the GH-treated group. However, after correction for age, height, weight, and presence of bicuspid aortic valve and coarctation, using a multiple regression, neither history of GH treatment nor the length of GH treatment had an effect on the aortic diameter. Weight (P = 0.02), height (P = 0.001), and presence of bicuspid aortic valve (P = 0.0001) were associated with larger ascending aortic diameter, whereas age (P = 0.008), height (P = 0.02), and history of coarctation (P = 0.006) were associated with larger descending aortic diameter. Conclusions: GH treatment of girls with TS does not seem to affect ascending or descending aortic diameter above the increase related to the larger body size.

UR - http://www.scopus.com/inward/record.url?scp=33646386665&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646386665&partnerID=8YFLogxK

U2 - 10.1210/jc.2005-2625

DO - 10.1210/jc.2005-2625

M3 - Article

C2 - 16507631

AN - SCOPUS:33646386665

VL - 91

SP - 1785

EP - 1788

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 5

ER -